Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis

To identify possible differences in cardiovascular (CV) risk among different insulin therapies, we performed pre-specified meta-analyses across the clinical program for basal insulin peglispro (BIL), in patien...

Source: Cardiovascular Diabetology - May 17, 2016 Category: Cardiology Authors: Byron J. Hoogwerf, A. Michael Lincoff, Angel Rodriguez, Lei Chen and Yongming Qu Source Type: research